Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
about
Inflammatory bowel disease and cancer: The role of inflammation, immunosuppression, and cancer treatmentManaging Patients With Psoriasis in the Busy Clinic: Practical Tips for Health Care PractitionersWhat is the impact of biologic therapies on common co-morbidities in patients with rheumatoid arthritis?Biologics registers in RA: methodological aspects, current role and future applications.Risk of malignancies using anti-TNF agents in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis: a systematic review and meta-analysis.[Medication treatment of rheumatoid arthritis with a history of malignancy. Epidemiological data].Biological treatment of Crohn's disease.TNF inhibitors to treat ulcerative colitis in a metastatic breast cancer patient: a case report and literature review.Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory SarcoidosisThe London Position Statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organization: when to start, when to stop, which drug to choose, and how to predict response?2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis.Cancer Recurrence Following Immune-Suppressive Therapies in Patients With Immune-Mediated Diseases: A Systematic Review and Meta-analysis.Do inflammatory bowel disease therapies cause cancer?Treating rheumatic patients with a malignancy.Risk of solid cancer in patients exposed to anti-tumour necrosis factor therapy: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Observational studies on the risk of cancer associated with tumor necrosis factor inhibitors in rheumatoid arthritis: a review of their methodologies and resultsMalignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: analysis of the Australian Rheumatology Association Database (ARAD) prospective cohort studyCancer risk in immune-mediated inflammatory diseases (IMID).Harms of TNF inhibitors in rheumatic diseases: a focused review of the literature.The BSRBR-RA at 15 years.The incidence of cancer in patients with rheumatoid arthritis and a prior malignancy who receive TNF inhibitors or rituximab: results from the British Society for Rheumatology Biologics Register-Rheumatoid Arthritis.Metastatic bone lesion due to methotrexate and etanercept 24 years after breast cancer treatment.The London position statement of the World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's and Colitis Organisation: safety.Safety of biologic therapy in rheumatoid arthritis.Treating to target in rheumatoid arthritis: biologic therapies.Certolizumab pegol for the treatment of rheumatoid arthritis.The practical value of biologics registries in Africa and Middle East: challenges and opportunities.Melanoma and rheumatoid arthritis (brief report).The management of immunosuppression in patients with inflammatory bowel disease and cancer.Management of inflammatory bowel disease in the elderly: do biologicals offer a better alternative?Targeting TNF-α for the treatment of inflammatory bowel disease.Certolizumab pegol in axial spondyloarthritis.Safety of synthetic and biological DMARDs: a systematic literature review informing the 2013 update of the EULAR recommendations for management of rheumatoid arthritis.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Etanercept: a review of its use in autoimmune inflammatory diseases.Does a personal or family history of malignancy preclude the use of immunomodulators and biologics in IBD.Safety considerations when using anti-TNFα therapy to treat Crohn's disease.Characteristics and risk factors of lymphoproliferative disorders among patients with rheumatoid arthritis concurrently treated with methotrexate: a nested case-control study of the IORRA cohort.Management of IBD in the Elderly Patient With Cancer.The risk of malignancy or progression of existing malignancy in patients with psoriasis treated with biologics: case report and review of the literature.
P2860
Q26745456-5723739C-26D9-4D63-BE99-18CF05B06994Q26771785-C75412FA-4AD9-43C5-8F2F-08DF0FDC97BBQ28074148-42BF917B-A0DE-4960-A3AB-F80267499060Q30234303-21A8F49B-BB79-4CC9-8C1D-C1C7947706DEQ30240212-0F5FC094-AEE1-45EA-869A-7C7B8A2D7C30Q31036951-A2110595-A20A-4997-B57B-5C8101C60CA2Q33354991-79ECB5B2-112C-4857-ABDB-AEE8BE5C4C72Q33626895-039C562F-0BEE-4CD0-9590-73940C96FA29Q34050113-B6B3C1C0-D866-46E5-9AE1-00B0893EF312Q34147687-E8C874F8-9258-4C79-ACA8-8CD1A750850AQ34500921-C501F21A-A2DB-40EC-A1C2-7ABE62488E99Q34520662-82C27202-84AF-4F17-896A-8CCF934BE3BFQ34613890-73C59165-33B2-42FE-A5FE-97D026600E53Q35557863-F47938C3-2F38-467F-914D-CDCDBE8D0068Q35605468-752D8F0A-754E-4D0D-B171-EB917FD5CB3FQ35621627-0D20031F-0E90-4CFA-8BB8-E54E83F193F3Q35813092-E67879C1-5EF0-46F8-9082-0906C83F3B37Q37153407-6AADC682-B43C-413D-AF0F-BB86F22E2928Q37189376-3C3ADD55-DEF7-4853-A335-432792ADF816Q37333943-072ED6C0-4677-4E43-A6BD-854805020783Q37383424-2EBBE8CB-9FB7-47FA-8A6C-F70548AC5E9CQ37704188-0D3CDF09-EED1-4671-AD60-B685FA5AA720Q37918330-08FFA802-A090-4C50-A3FE-6B8DAF586C1FQ37944433-054E6566-691F-4B8A-9527-6CAAA5FA3BCCQ37954077-9ED81412-6ABF-45EA-8798-4F8051B0522EQ37967946-D7E50A66-AB4A-4ECD-8653-D0FA54FD5703Q37974121-F93174B0-C068-4141-87C4-4A69A89C5BAAQ37975474-6E3E9115-3579-4A52-B803-38F5CD601B3AQ38125570-8B756F06-ABA4-4454-BE4B-1F707F81CA02Q38141975-45C8A54D-950D-40C1-9CCB-36FCD38257E7Q38160905-0A191B69-4059-4A11-84AE-0D02B1586E01Q38161555-B58780A6-104F-437A-8BA3-451385B55BE5Q38176745-D3675EA6-353F-42F3-BD14-02F447F23912Q38197891-BA013EFB-2AAD-4256-AF68-ACC43895711CQ38230740-235D8853-610C-44E7-B3C4-E54CFC6E2D69Q38253832-7CED7F9A-96A4-44C8-B927-B8B9137C6685Q38268598-99FC649D-5243-429D-9201-CB49BE464B46Q38401295-ACF80EF5-B133-46A4-946A-FE3F142E9F82Q38541901-B8D2750B-225C-4F7B-B6FA-A626457D8261Q38681514-505D9FF6-C3AD-4943-8AC1-6E680993402A
P2860
Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Influence of anti-tumor necros ...... eumatology Biologics Register.
@ast
Influence of anti-tumor necros ...... eumatology Biologics Register.
@en
Influence of anti-tumor necros ...... eumatology Biologics Register.
@nl
type
label
Influence of anti-tumor necros ...... eumatology Biologics Register.
@ast
Influence of anti-tumor necros ...... eumatology Biologics Register.
@en
Influence of anti-tumor necros ...... eumatology Biologics Register.
@nl
prefLabel
Influence of anti-tumor necros ...... eumatology Biologics Register.
@ast
Influence of anti-tumor necros ...... eumatology Biologics Register.
@en
Influence of anti-tumor necros ...... eumatology Biologics Register.
@nl
P2093
P2860
P50
P356
P1476
Influence of anti-tumor necros ...... heumatology Biologics Register
@en
P2093
British Society For Rheumatology Biologics Register Control Centre Consortium
British Society for Rheumatology Biologics Register
K D Watson
K L Hyrich
L K Mercer
P2860
P304
P356
10.1002/ACR.20129
P577
2010-06-01T00:00:00Z